News archive
Showing 697 results
May 2011
-
Media Release
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate1,2Regulatory filings for the use of ACZ885 in… -
Media Release
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
-
Media Release
Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
New professional cycling team, called NOW and Novartis for MS, to compete nationally and ride tandem with MS patients in National MS Society’s bike rides Program kicks-off on the eve of World MS Day… -
Media Release
Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
-
Media Release
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
- Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin(1)- Afinitor represents a new approach to… -
Media Release
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
April 2011
-
Media Release
Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
Gilenya delayed the progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment11 scientific abstracts on Gilenya… -
Media Release
Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
March 2011
-
Media Release
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149[1]COPD is a progressive and life-threatening lung… -
Media Release
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
January 2011
-
Media Release
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
East Hanover, NJ, January 10, 2011 – Novartis Pharmaceuticals Corporation (Novartis) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks… -
Media Release
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products